Zoetis Inc. (ZTS)
NYSE: ZTS · IEX Real-Time Price · USD
179.04
+1.30 (0.73%)
Jul 12, 2024, 4:00 PM EDT - Market closed

Company Description

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.

The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.

In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health.

It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health.

Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Inc.
Zoetis logo
Country United States
Founded 1952
IPO Date Feb 1, 2013
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 14,100
CEO Ms. Kristin C. Peck

Contact Details

Address:
10 Sylvan Way
Parsippany, New Jersey 07054
United States
Phone 973-822-7000
Website zoetis.com

Stock Details

Ticker Symbol ZTS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001555280
CUSIP Number 98978V103
ISIN Number US98978V1035
Employer ID 46-0696167
SIC Code 2834

Key Executives

Name Position
Kristin C. Peck Chief Executive Officer and Director
Wetteny N. Joseph Executive Vice President and Chief Financial Officer
Wafaa Mamilli EVice President, Chief Digital and Tech. Officer, Group President for China, Brazil and Preci. Animal Health
Heidi C. Chen Executive Vice President, General Counsel, Corporate Secretary and Business Lead of Human Health Diagnostics
Dr. Robert J. Polzer Ph.D. Executive Vice President and President of Research and Development
Roxanne Lagano Executive Vice President and Chief Human Resources Officer and Global Operations
Steven Frank Vice President of Investor Relations
William Price Vice President and Chief Communications Officer
Jeannette Ferran Astorga Executive Vice President of Corporate Affairs and Communications and Chief Sustainability Officer
Nick Ashton Executive Vice President and President of Global Manufacturing and Supply

Latest SEC Filings

Date Type Title
Jun 26, 2024 11-K Annual report of employee stock purchase, savings and similar plans
May 30, 2024 SD Form - SD
May 24, 2024 8-K Current Report
May 23, 2024 8-K Current Report
May 22, 2024 8-K Current Report
May 8, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 7, 2024 144 Filing
May 6, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 2, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report